PL3296299T3 - Krystaliczna postać 3-etylo-4-{3-izopropylo-4-(4-(1-metylo-1H-pirazol-4-ilo)-1H-imidazol-1-ilo)-1H-pirazolo[3,4-b]pirydyn-1-ylo}benzamidu - Google Patents
Krystaliczna postać 3-etylo-4-{3-izopropylo-4-(4-(1-metylo-1H-pirazol-4-ilo)-1H-imidazol-1-ilo)-1H-pirazolo[3,4-b]pirydyn-1-ylo}benzamiduInfo
- Publication number
- PL3296299T3 PL3296299T3 PL16792715T PL16792715T PL3296299T3 PL 3296299 T3 PL3296299 T3 PL 3296299T3 PL 16792715 T PL16792715 T PL 16792715T PL 16792715 T PL16792715 T PL 16792715T PL 3296299 T3 PL3296299 T3 PL 3296299T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazolo
- pyrazol
- benzamide
- imidazol
- pyridin
- Prior art date
Links
- NVVPMZUGELHVMH-UHFFFAOYSA-N 3-ethyl-4-[4-[4-(1-methylpyrazol-4-yl)imidazol-1-yl]-3-propan-2-ylpyrazolo[3,4-b]pyridin-1-yl]benzamide Chemical compound CCC1=CC(C(N)=O)=CC=C1N1C2=NC=CC(N3C=C(N=C3)C3=CN(C)N=C3)=C2C(C(C)C)=N1 NVVPMZUGELHVMH-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015097521 | 2015-05-12 | ||
| PCT/JP2016/063989 WO2016181990A1 (ja) | 2015-05-12 | 2016-05-11 | アザ二環式化合物の結晶 |
| EP16792715.1A EP3296299B1 (en) | 2015-05-12 | 2016-05-11 | Crystal form of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h-imidazol-1-yl)-1h-pyrazolo[3,4-b]pyridin-1-yl}benzamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3296299T3 true PL3296299T3 (pl) | 2020-04-30 |
Family
ID=57248173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16792715T PL3296299T3 (pl) | 2015-05-12 | 2016-05-11 | Krystaliczna postać 3-etylo-4-{3-izopropylo-4-(4-(1-metylo-1H-pirazol-4-ilo)-1H-imidazol-1-ilo)-1H-pirazolo[3,4-b]pirydyn-1-ylo}benzamidu |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10526324B2 (pl) |
| EP (1) | EP3296299B1 (pl) |
| JP (1) | JP6537601B2 (pl) |
| KR (1) | KR102089254B1 (pl) |
| CN (1) | CN107531707B (pl) |
| AU (1) | AU2016260279B2 (pl) |
| BR (1) | BR112017024367B1 (pl) |
| CA (1) | CA2985033C (pl) |
| DK (1) | DK3296299T3 (pl) |
| ES (1) | ES2760503T3 (pl) |
| HU (1) | HUE047855T2 (pl) |
| MX (1) | MX381000B (pl) |
| MY (1) | MY189352A (pl) |
| PH (1) | PH12017502007A1 (pl) |
| PL (1) | PL3296299T3 (pl) |
| PT (1) | PT3296299T (pl) |
| RU (1) | RU2697521C2 (pl) |
| SG (1) | SG11201708793SA (pl) |
| TW (1) | TWI659954B (pl) |
| WO (1) | WO2016181990A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3016353C (en) | 2016-03-25 | 2021-04-27 | Intra-Cellular Therapies, Inc. | Deuterated fused heterocycle gamma-carbolines and compositions thereof useful in the treatment of nervous system disorders |
| WO2019054465A1 (ja) * | 2017-09-15 | 2019-03-21 | 大鵬薬品工業株式会社 | Ｉｄｏの発現が関与する疾患の予防及び／又は治療剤 |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| KR20210052472A (ko) | 2018-08-31 | 2021-05-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| AU2020311894B2 (en) | 2019-07-07 | 2025-06-26 | Intra-Cellular Therapies, Inc. | Novel methods |
| US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| CA3189457A1 (en) * | 2020-07-15 | 2022-01-20 | Taiho Pharmaceutical Co., Ltd. | Crystal of pyrimidine compound |
| CN114685492A (zh) * | 2020-12-31 | 2022-07-01 | 杭州领业医药科技有限公司 | Tas-116的晶型及其制备方法、药物组合物和用途 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| US20250353843A1 (en) | 2022-06-10 | 2025-11-20 | Taiho Pharmaceutical Co., Ltd. | Analogues of azabicyclic compounds |
| TW202404585A (zh) | 2022-06-10 | 2024-02-01 | 日商大鵬藥品工業股份有限公司 | 含有匹密特匹（Pimitespib）之醫藥組合物 |
| CN115960100B (zh) * | 2022-12-28 | 2023-08-18 | 北京康立生医药技术开发有限公司 | 一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05002887A (es) | 2002-09-16 | 2005-05-27 | Glaxo Group Ltd | Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa. |
| RU2357967C2 (ru) | 2002-09-16 | 2009-06-10 | Глаксо Груп Лимитед | ПРОИЗВОДНЫЕ ПИРАЗОЛО[3, 4-b]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ), ПРИМЕНЕНИЕ (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ) |
| MY152972A (en) * | 2009-07-10 | 2014-12-15 | Taiho Pharmaceutical Co Ltd | Azabicyclo compound and salt thereof |
| EP2662357B1 (en) * | 2011-01-07 | 2016-08-03 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compounds or salts thereof for use in the treatment of cancer |
| RU2657783C2 (ru) * | 2013-09-30 | 2018-06-15 | Тайхо Фармасьютикал Ко., Лтд. | Комбинированная терапия с использованием азабициклосоединения для ракового заболевания |
-
2016
- 2016-05-11 JP JP2017517963A patent/JP6537601B2/ja active Active
- 2016-05-11 RU RU2017142958A patent/RU2697521C2/ru active
- 2016-05-11 EP EP16792715.1A patent/EP3296299B1/en active Active
- 2016-05-11 PL PL16792715T patent/PL3296299T3/pl unknown
- 2016-05-11 BR BR112017024367-9A patent/BR112017024367B1/pt active IP Right Grant
- 2016-05-11 AU AU2016260279A patent/AU2016260279B2/en active Active
- 2016-05-11 SG SG11201708793SA patent/SG11201708793SA/en unknown
- 2016-05-11 US US15/572,398 patent/US10526324B2/en active Active
- 2016-05-11 MX MX2017014438A patent/MX381000B/es unknown
- 2016-05-11 MY MYPI2017704085A patent/MY189352A/en unknown
- 2016-05-11 ES ES16792715T patent/ES2760503T3/es active Active
- 2016-05-11 WO PCT/JP2016/063989 patent/WO2016181990A1/ja not_active Ceased
- 2016-05-11 CA CA2985033A patent/CA2985033C/en active Active
- 2016-05-11 HU HUE16792715A patent/HUE047855T2/hu unknown
- 2016-05-11 PT PT167927151T patent/PT3296299T/pt unknown
- 2016-05-11 KR KR1020177032411A patent/KR102089254B1/ko active Active
- 2016-05-11 DK DK16792715.1T patent/DK3296299T3/da active
- 2016-05-11 CN CN201680027213.0A patent/CN107531707B/zh active Active
- 2016-05-11 TW TW105114603A patent/TWI659954B/zh active
-
2017
- 2017-11-03 PH PH12017502007A patent/PH12017502007A1/en unknown
-
2019
- 2019-11-29 US US16/699,421 patent/US10947233B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3296299T (pt) | Forma cristalina de 3-etil-4-{3-isopropil-4-(4-(1-metil-1hpirazol- 4-il)-1h-imidazol-1-il)-1h-pirazolo[3,4-b]piridin- 1-il}benzamida | |
| IL274771A (en) | Use of pyrazolopyrimidine derivatives for the treatment of PI3Kδ associated disorders | |
| HUS2200054I1 (hu) | 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése | |
| IL240010B (en) | Sulfonyl-2-(1h-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide compounds for the treatment of cancer and autoimmune diseases | |
| IL240397A0 (en) | Forms of methyl {6,4-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [[b-4,3-pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | |
| PL3154970T3 (pl) | Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnych | |
| IL251164A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
| IL247155A0 (en) | Rapamycin for the treatment of lymphangioleiomyomatosis | |
| IL251385A0 (en) | An inhaled formulation of rapamycin for the treatment of pulmonary hypertension | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| PL2812013T3 (pl) | Formulacja do leczenia ibs | |
| IL258070A (en) | Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide | |
| IL251166B (en) | Imidazo–[4,5–c]pyridine derivatives as inhibitors of ssao | |
| IL244619A0 (en) | Pyrido[3-b,4]pyrazine-2-carboxamides as neurogenic agents for the treatment of neurodegenerative disorders | |
| HUP1400378A2 (hu) | Eljárás apixaban elõállítására | |
| GB201809834D0 (en) | Novel crystalline form of the thifensulfuron-methyl, process for preparation and use thereof | |
| HUE055175T2 (hu) | Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája |